Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of C$0.07 and traded as low as C$0.06. Hemostemix shares last traded at C$0.06, with a volume of 1,000 shares changing hands.
Hemostemix Price Performance
The company has a 50 day moving average of C$0.07 and a 200-day moving average of C$0.06. The stock has a market capitalization of C$11.63 million, a P/E ratio of -2.12 and a beta of 0.50. The company has a quick ratio of 0.48, a current ratio of 0.13 and a debt-to-equity ratio of -61.85.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
